LOGIN
Tocilizumab treatment in systemic juvenile idiopathic arthritis
May 2013
Tocilizumab treatment in systemic juvenile idiopathic arthritis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
N Engl J Med. 2012 Dec 20;367(25):2385-95. doi: 10.1056/NEJMoa1112802Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
112 children, ages 2-17, suffering from active systemic juvenile idiopathic arthritis (JIA) for longer than 6 months with inadequate responses to non-steroidal anti-inflammatory drugs were included in this trial. In the first 12 week randomized double blind phase, participants were treated every 2 weeks with ether anti–interleukin-6 receptor antibody tocilizumab or with a placebo given intravenous...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.